Nocturnal Hypertension Clinical Trial
Official title:
Evaluation of Nocturnal Hypertension With 24-hour Ambulatory or Home Blood Pressure Measurement: Correlation With Target-Organ Damage
The aim of this study is to evaluate nocturnal hypertension with 24-hour ambulatory blood pressure and home blood pressure (BP) measurements through a) comparison of mean BP and nocturnal dipping assessed with the two methods, b) correlation of those parameters with parameters of target-organ damage and c) comparison of the potential of the two methods to define non-dippers.
It is well known that blood pressure (BP) exhibits diurnal variation. Nocturnal fall of BP
normally exceeds 10%. Subjects with such fall of BP during sleep are classified as "dippers"
and those with a nocturnal fall of BP less than 10% are classified as "non-dippers".
Non-dippers are exposed to a greater cardiovascular risk. To date dipping status is defined
with 24-hour ambulatory BP monitoring (ABPM). Many studies have shown that Home BP
monitoring (HBPM) can be an alternative to daytime ambulatory BP monitoring and it exhibits
similar correlation to markers of hypertension target-organ-damage (TOD). Nocturnal
hypertension shows closer correlation with TOD, than daytime hypertension. In this study
patients will be provided with a new-technology, reliable oscillometric device for HBPM,
equipped with a modified algorithm, which allows scheduled automated BP measurements during
sleep (Microlife WatchBP Home Nocturnal). Duplicate morning and evening BP measurements with
one-minute interval will be performed by the patient sitting during seven working days.
Afterwards a 24-hour ABPM will be performed, using Microlife WatchBP O3 oscillometric
device, with a 20-minute interval between measurements. This order may be reversed according
to the wish of the patient and devices' availability. Participants will visit site 3 times.
Office blood pressure will be measured during two visits. Triplicate measurements with
Microlife WatchBP Home Nocturnal will be performed at the sitting position.
TOD will be assessed with:
- cardiac triplex (LVMI)
- carotid triplex (ΙΜΤ)
- pulse wave velocity.
- Albumin/creatinine ratio measured in morning urine sample.
;
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03050229 -
SGLT-2i and ARB Combination Therapy in Patients With T2DM and Nocturnal Hypertension (SACRA Study)
|
Phase 4 | |
Recruiting |
NCT04137549 -
Registry Study on "Control Nocturnal Hypertension to Reach the Target "
|